Guidelines developed in partnership with
Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer. Sydney: Cancer Council Australia. [Version URL: http://wiki.cancer.org.au/australiawiki/index.php?oldid=122823, cited 2021 Jan 21]. Available from: https://wiki.cancer.org.au/australia/Guidelines:PSA_Testing/Risk/Discussion.
This resource has been developed, reviewed or revised more than five years ago. It may no longer reflect current evidence or best practice.
National Health and Medical Research Council
These guidelines (recommendations) in the web-version of this guideline were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 2 November 2015 under section 14A of the National Health and Medical Research Council Act 1992 In approving the guidelines (recommendations), NHMRC considers that they meet the NHMRC standard for clinical practice guidelines. This approval is valid for a period of five years. NHMRC is satisfied that the guidelines (recommendations) are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for health professionals practising in an Australian health care setting.This publication reflects the views of the authors and not necessarily the views of the Australian Government.
The degree to which increased PSA testing of asymptomatic men with a family history of prostate cancer contributes to, or explains, their observed increased probability of being diagnosed with prostate cancer is unknown.
Future research priorities
The contribution of increased PSA testing of asymptomatic men with a family history to the observed increased probability of being diagnosed with prostate cancer needs to be quantified. This could be achieved through long-term prospective cohort studies of Australian men.